TITLE

CDRI licenses novel anti malarial compound to IPCA

PUB. DATE
September 2007
SOURCE
Chemical Business;Sep2007, Vol. 21 Issue 9, p81
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a collaborative license agreement entered into by Central Drug Research Institute (CDRI) with Ipca Laboratories Ltd. for further development of its anti-malarial compound 99/411. The compound is a synthetic substitute for drugs based on Artemisinin, which is derived from the Artemisia annua plant. A synthetic substitute of artemisinin is said to allow cost effective management of P. falciparum malaria.
ACCESSION #
27134346

 

Related Articles

  • After Malaria, the Growth Fever.  // Business Today;8/8/2010, Vol. 19 Issue 16, p88 

    The article reports on the strong growth of the pharmaceutical company Ipca Laboratories Ltd. due to its anti-malaria drugs Lariago in India.

  • WHO Approves Artemisinin for Malaria in Africa. Purcell, Katherine // HerbalGram;Fall2004, Issue 64, p19 

    Reports that the World Health Organization and the United Nations Children's Fund have started to consider the use of purified bioactive substances from the herb Sweet Annie or Artemisia annua L., Asteraceae as a first-line treatment for malaria in Africa. Derivation of the compound artemisinin...

  • Fansidar.  // Royal Society of Medicine: Medicines;2002, p241 

    This article presents information on Fansidar, a proprietary, prescription-only compound preparation of the antimalarial drug pyrimethamine and the sulfadoxine. It can be used to treat patients who are seriously ill with malaria, and is available as tablets. It is manufactured by Roche.

  • Scripps Research scientists identify new class of antimalarial compounds.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p418 

    The article reports on a study conducted by scientists at the Genomics Institute of the Novartis Research Foundation (GNF) and the Scripps Research Institute which examines the potential treatment of malaria. Findings reveal a new class of chemical compounds which can alleviate the symptom of...

  • Antimalarial natural products: a review. Mojab, Faraz // Avicenna Journal of Phytomedicine;Spring2012, Vol. 2 Issue 2, p52 

    Objective: Malaria is an infectious disease commonplace in tropical countries. For many years, major antimalarial drugs consisted of natural products, but since 1930s these drugs have been largely replaced with a series of synthetic drugs. This article tries to briefly indicate that some plants...

  • Arterolane, a New Synthetic Trioxolane for Treatment of Uncomplicated Plasmodium falciparum Malaria: A Phase II, Multicenter, Randomized, Dose-Finding Clinical Trial. Valecha, Neena; Looareesuwan, Sornchai; Martensson, Andreas; Abdulla, Salim Mohammed; Krudsood, Srivicha; Tangpukdee, Noppadon; Mohanty, Sanjib; Mishra, Saroj K.; Tyagi, P. K.; Sharma, S. K.; Moehrle, Joerg; Gautam, Anirudh; Roy, Arjun; Paliwal, Jyoti K.; Kothari, Monica; Saha, Nilanjan; Dash, Aditya P.; Bj√∂rkman, Anders // Clinical Infectious Diseases;9/15/2010, Vol. 51 Issue 6, p684 

    Background. Drug-resistant Plasmodium falciparum malaria necessitates development of novel drugs for treatment. The present study assessed the efficacy and safety of 3 dose levels of arterolane (RBx 11160), a synthetic trioxolane, for treatment of acute uncomplicated falciparum malaria. Methods....

  • Ipca Labs stops API exports to US from Ratlam unit.  // FRPT- Chemical Snapshot;8/10/2014, p22 

    The article reports on the decision of Ipca Laboratories to suspend its exports of active pharmaceutical ingredients (API) to the U.S. from its plant at Ratlam in Madhya Pradesh, India after the U.S. Food and Dug Administration (FDA) found company violation of standard production guidelines.

  • Ipca Laboratories to set up R&D centre.  // Chemical Business;Jul95, Vol. 8 Issue 12, p88 

    Reports on Ipca Laboratories' construction of a research and development center in Bombay at Kandiavli, India. Purchase of a bulk drugs plant at Indore; Plans for an increased capacity in the plant.

  • Ipca Labs expands its anti-malarial range.  // Chemical Business;Nov98, Vol. 12 Issue 11, p70 

    Reports on IPCA Laboratories' launching of a product based on artemether made from a Chinese herb.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics